A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTG-200 in Normal Healthy Male Volunteers
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs PTG 200 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Protagonist Therapeutics
- 10 Oct 2017 Status changed from planning to not yet recruiting.
- 20 Sep 2017 According to a Protagonist Therapeutics media release, this trial is expected to begin before end of 2017.
- 04 May 2017 According to a Protagonist Therapeutics media release, this trial is expected to begin in the second half of 2017.